PS-072 Incidence, management and cost of Telaprevir/Boceprevir-Induced thrombocytopenia during the first 12 weeks of treatment in patients with hepatitis C
PS-072 Incidence, management and cost of Telaprevir/Boceprevir-Induced thrombocytopenia during the first 12 weeks of treatment in patients with hepatitis C